Yes, I noticed that. There'll be an amendment required for sure. I also wouldn't put any money on the Scoping Study coming through this quarter either. Frankly I was amazed that they were able to spin-off WR1 successfully. Everything else always seems to occur months after forecasted dates. I do give them some leeway, though, where assays are concerned because so many companies are having trouble getting them through an obvious shortage of labs and trained personnel.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
14.5¢ |
Change
0.015(11.5%) |
Mkt cap ! $30.26M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 14.5¢ | 13.0¢ | $4.435K | 34K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8888 | 13.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.5¢ | 118807 | 4 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| MTC (ASX) Chart |